Please enter your name.
Please enter a valid email address.
Please select an issue type.
Please add a few details about the issue.
About Combat Drugs
Combat Drugs is a publicly listed company based in Hyderabad (India) founded in 1986. Formulations are manufactured and custom services are provided in pharmaceuticals. The company has 21 employees. Its Indian entity Icp Solutions Limited reported revenue of ₹9.89 Cr. Its focus areas include Diversified Pharmaceuticals.
Company details
Combat Drugs was established in 1986 in Hyderabad, India, within the pharmaceutical sector. Branded formulations are produced alongside custom manufacturing services. Operations encompass solid dosage forms, including single- and multi-ingredient tablets and capsules in various coatings and designs, as well as liquid orals and ointments. Focus is placed on meeting formulation needs through these categories.
- Headquarters Hyderabad, India
- Employees 21
- Stage Public
- SectorsHealthcare
- Website combatdrugs.in
- Social LinkedIn
- Legal Name Icp Solutions Limited
- Date of Incorporation 25 May, 2018
- Jurisdiction Hyderabad, Telangana, India
Operational Areas
Key Metrics
- Market Cap₹5.90 Cr
DECIPHER · BSE
- Share Price₹5.67
-2.91% today
- Revenue₹14.05 Cr
FY 2025-26 · -37.9% YoY
- EBITDA−₹3.39 Cr
Margin -24.1%
- Net Profit−₹3.09 Cr
FY 2025-26 · -1288.5% YoY
- Employee Count21
Associated legal entities of Combat Drugs
Combat Drugs is associated with 2 registered companies on The Company Check; the primary company is Icp Solutions Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Icp Solutions Limited CIN U72500TG2018PLC124743 | Active | 25 May 2018 | Hyderabad, Telangana | ₹9.9 Cr | 21 | 6 | View details |
| Decipher Labs Limited Listed CIN L24230TG1986PLC006781 | Active | 17 Sep 1986 | Hyderabad, Telangana | ₹14.3 Cr | 5 | 7 | View details |
Board of directors of Icp Solutions Limited (Combat Drugs)
Icp Solutions Limited is the primary company behind Combat Drugs. The boards of the 2 registered companies of Combat Drugs currently have 8 directors; the longest-serving is Sushant Mohan Lal, appointed in 2006. 29 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sushant Mohan Lal DIN 01227151 | Director | 19 May 2006 | 20 yrs 5 mo | Decipher Labs Limited |
| Sridhara Tulasi Priyanka DIN 08883973 | Whole-time director | 21 Sep 2020 | 6 yrs 1 mo | Icp Solutions Limited |
| Venkateswara Rao Gudipudi DIN 02147615 | Director | 13 Aug 2022 | 4 yrs 3 mo | Decipher Labs Limited |
| Abhichakra Gudipudi DIN 07761348 | Director | 16 Aug 2022 | 4 yrs 2 mo | Icp Solutions Limited |
| Janaki Ram Ajjarapu DIN 02155939 | Managing Director | 16 Aug 2022 | 4 yrs 2 mo | Icp Solutions Limited, Decipher Labs Limited |
| Lakshmi Vijaya Nimmala DIN 09788849 | Director | 14 Feb 2023 | 3 yrs 9 mo | Decipher Labs Limited |
| Gayathri Raghuram DIN 09775806 | Director | 04 Sep 2023 | 3 yrs 2 mo | Decipher Labs Limited |
| Dalavath Amar Singh DIN 02206249 | Whole-time director | 13 Nov 2025 | 1 yr | Decipher Labs Limited |
IPO & Listings of Combat Drugs
Combat Drugs is a publicly listed company on the BSE with ticker symbol DECIPHER in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onBSE: DECIPHER
- Listed entityDecipher Labs Limited
- Exchange sectorPharmaceuticals
Financials of Combat Drugs
Exchange-reported figures of Decipher Labs Limited, the listed company behind Combat Drugs (BSE: DECIPHER).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹14.05 Cr
-37.9% YoY
EBITDA
−₹3.39 Cr
+53.1% YoY
Profit After Tax
−₹3.09 Cr
-1288.5% YoY
Net Worth
₹20.67 Cr
-9.6% YoY
Total Assets
₹21.17 Cr
-8.4% YoY
Total Debt
₹0.50 Cr
+108.3% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 14.05 | 22.61 | 35.88 | 45.57 | 65.32 | 55.56 | 23.99 |
| Revenue growth | -37.9% | -37.0% | -21.3% | -30.2% | +17.6% | +131.6% | - |
| EBITDA | (3.39) | (7.23) | (0.94) | (10.62) | 6.02 | 3.49 | 2.53 |
| EBITDA margin | -24.1% | -32.0% | -2.6% | -23.3% | +9.2% | +6.3% | +10.6% |
| Profit before tax | (3.69) | (6.39) | (1.21) | (4.16) | 12.34 | 2.15 | 1.47 |
| Net profit | (3.09) | 0.26 | (1.51) | 3.77 | 11.37 | 1.41 | 1.10 |
| Net profit margin | -22.0% | +1.2% | -4.2% | +8.3% | +17.4% | +2.5% | +4.6% |
| EPS (₹) | (3.05) | (5.03) | (1.66) | (2.66) | 11.27 | 1.39 | 1.09 |
| Balance sheet | |||||||
| Total assets | 21.17 | 23.10 | 21.86 | 24.16 | 34.49 | 30.08 | 23.84 |
| Net worth | 20.67 | 22.86 | 21.86 | 23.21 | 24.17 | 13.69 | 12.56 |
| Total debt | 0.50 | 0.24 | 0.00 | 0.95 | 10.32 | 16.39 | 11.28 |
| Cash & bank | 0.74 | 2.81 | 9.31 | 7.42 | 15.41 | 6.98 | 1.47 |
| Net working capital | 15.95 | 18.39 | 12.90 | 16.07 | 30.76 | 13.90 | 11.13 |
| Cash flow | |||||||
| Cash from operations | (2.45) | (9.82) | 4.85 | (1.56) | 8.26 | 1.83 | (15.18) |
| Cash from investing | (0.24) | 3.07 | (1.79) | (4.28) | (1.13) | (0.31) | (0.01) |
| Cash from financing | 0.00 | 0.24 | (1.17) | (2.15) | 1.30 | 3.99 | 16.36 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.41 | 3.60 | 3.21 | 4.31 | 2.92 | 3.50 | 5.80 | 5.87 |
| Revenue growth (YoY) | -17.5% | +2.9% | -44.7% | -26.6% | -60.8% | - | - | - |
| Other income | 0.10 | 0.17 | 0.02 | 0.02 | 0.01 | 0.87 | 0.17 | 0.12 |
| EBITDA | (2.16) | 0.22 | (0.43) | 0.12 | (3.32) | (6.58) | (0.64) | (1.33) |
| EBITDA margin | -89.6% | +6.1% | -13.4% | +2.8% | -113.7% | -188.0% | -11.0% | -22.7% |
| Depreciation | 0.13 | 0.15 | 0.13 | 0.13 | 0.12 | 0.13 | 0.12 | 0.12 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (2.19) | 0.24 | (0.54) | 0.01 | (3.43) | (5.84) | (0.59) | (1.33) |
| Tax | 0.00 | 0.61 | 0.01 | 0.00 | 0.00 | (1.73) | 0.01 | 0.00 |
| Net profit | (2.19) | (0.37) | (0.55) | 0.01 | (3.43) | (4.11) | (0.60) | (1.33) |
| EPS (₹) | (2.16) | (0.35) | (0.53) | 0.02 | (3.39) | (4.07) | (0.59) | (1.31) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1.14 | 0.85 | 3.53 | 0.81 | 0.99 | 0.98 | 1.42 |
| Revenue growth | +34.1% | -75.9% | +335.8% | -18.2% | +1.0% | -31.0% | - |
| EBITDA | (0.22) | (0.45) | 0.02 | (2.60) | 0.36 | 0.03 | 0.16 |
| EBITDA margin | -19.3% | -52.9% | +0.6% | -321.0% | +36.4% | +3.1% | +11.3% |
| Profit before tax | (0.24) | (0.45) | 0.03 | (2.63) | 0.36 | 0.11 | 0.17 |
| Net profit | (0.25) | (0.45) | 0.03 | (0.30) | 0.36 | 0.11 | 0.17 |
| Net profit margin | -21.9% | -52.9% | +0.9% | -37.0% | +36.4% | +11.2% | +12.0% |
| EPS (₹) | (0.24) | (0.44) | 0.02 | (2.59) | 0.36 | 0.10 | 0.17 |
| Balance sheet | |||||||
| Total assets | 8.74 | 8.73 | 8.93 | 8.90 | 11.52 | 11.30 | 11.30 |
| Net worth | 8.24 | 8.49 | 8.93 | 8.90 | 11.52 | 11.16 | 11.07 |
| Total debt | 0.50 | 0.24 | 0.00 | 0.00 | 0.00 | 0.14 | 0.23 |
| Cash & bank | 0.03 | 0.05 | 0.03 | 0.06 | 0.05 | 0.02 | 0.03 |
| Net working capital | (0.09) | (0.13) | 0.15 | 0.10 | 2.52 | 2.62 | 2.77 |
| Cash flow | |||||||
| Cash from operations | (0.29) | (0.17) | (0.03) | (0.08) | 0.55 | 0.27 | (0.01) |
| Cash from investing | 0.00 | (0.05) | 0.00 | 0.09 | (0.38) | (0.19) | (0.07) |
| Cash from financing | 0.26 | 0.24 | 0.00 | 0.00 | (0.14) | (0.09) | 0.09 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.07 | 0.13 | 0.09 | 0.85 | 0.23 | 0.16 | 0.08 |
| Revenue growth (YoY) | -88.2% | -69.6% | -18.8% | +12.5% | +123.7% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Total expenses | 0.17 | 0.24 | 0.14 | 0.20 | 0.78 | 0.39 | 0.25 | 0.15 |
| EBITDA | (0.07) | (0.17) | (0.01) | (0.11) | 0.07 | (0.16) | (0.09) | (0.07) |
| EBITDA margin | -70.0% | -242.9% | -7.7% | -122.2% | +8.2% | -69.6% | -56.3% | -87.5% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.07) | (0.17) | (0.01) | (0.11) | 0.07 | (0.16) | (0.09) | (0.05) |
| Tax | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 14 Nov 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.41 | 3.60 | 3.21 | 4.31 | 2.92 | 3.50 | 5.80 | 5.87 |
| Revenue growth (YoY) | -17.5% | +2.9% | -44.7% | -26.6% | -60.8% | - | - | - |
| Other income | 0.10 | 0.17 | 0.02 | 0.02 | 0.01 | 0.87 | 0.17 | 0.12 |
| EBITDA | (2.16) | 0.22 | (0.43) | 0.12 | (3.32) | (6.58) | (0.64) | (1.33) |
| EBITDA margin | -89.6% | +6.1% | -13.4% | +2.8% | -113.7% | -188.0% | -11.0% | -22.7% |
| Depreciation | 0.13 | 0.15 | 0.13 | 0.13 | 0.12 | 0.13 | 0.12 | 0.12 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (2.19) | 0.24 | (0.54) | 0.01 | (3.43) | (5.84) | (0.59) | (1.33) |
| Tax | 0.00 | 0.61 | 0.01 | 0.00 | 0.00 | (1.73) | 0.01 | 0.00 |
| Net profit | (2.19) | (0.37) | (0.55) | 0.01 | (3.43) | (4.11) | (0.60) | (1.33) |
| EPS (₹) | (2.16) | (0.35) | (0.53) | 0.02 | (3.39) | (4.07) | (0.59) | (1.31) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 14.05 | 22.61 | 35.88 | 45.57 | 65.32 | 55.56 | 23.99 |
| Revenue growth | -37.9% | -37.0% | -21.3% | -30.2% | +17.6% | +131.6% | - |
| Other income | 0.22 | 1.32 | 0.42 | 7.37 | 7.67 | 0.65 | 0.27 |
| Total expenses | 17.44 | 29.84 | 36.82 | 56.19 | 59.30 | 52.07 | 21.46 |
| Employee cost | 0.00 | 21.32 | 27.75 | 41.16 | 47.46 | 47.34 | 19.32 |
| EBITDA | (3.39) | (7.23) | (0.94) | (10.62) | 6.02 | 3.49 | 2.53 |
| EBITDA margin | -24.1% | -32.0% | -2.6% | -23.3% | +9.2% | +6.3% | +10.6% |
| Depreciation | 0.52 | 0.48 | 0.45 | 0.43 | 0.87 | 0.82 | 0.56 |
| Interest | 0.00 | 0.00 | 0.24 | 0.48 | 0.48 | 1.17 | 0.77 |
| Profit before tax | (3.69) | (6.39) | (1.21) | (4.16) | 12.34 | 2.15 | 1.47 |
| Tax | (0.60) | (1.31) | 0.46 | (1.48) | 0.97 | 0.74 | 0.37 |
| Net profit | (3.09) | 0.26 | (1.51) | 3.77 | 11.37 | 1.41 | 1.10 |
| Net profit margin | -22.0% | +1.2% | -4.2% | +8.3% | +17.4% | +2.5% | +4.6% |
| EPS (₹) | (3.05) | (5.03) | (1.66) | (2.66) | 11.27 | 1.39 | 1.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves & surplus | 10.57 | 12.76 | 11.76 | 13.11 | 14.07 | 3.59 | 2.46 |
| Shareholders' funds (net worth) | 20.67 | 22.86 | 21.86 | 23.21 | 24.17 | 13.69 | 12.56 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.50 | 0.24 | 0.00 | 0.95 | 10.32 | 16.39 | 11.28 |
| Total debt | 0.50 | 0.24 | 0.00 | 0.95 | 10.32 | 16.39 | 11.28 |
| Total liabilities | 21.17 | 23.10 | 21.86 | 24.16 | 34.49 | 30.08 | 23.84 |
| Assets | |||||||
| Gross block | 2.72 | 2.89 | 3.14 | 3.46 | 2.92 | 4.51 | 4.99 |
| Net block | 2.26 | 2.55 | 2.91 | 3.32 | 2.83 | 4.44 | 4.98 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.26 | 0.26 | 3.39 | 3.76 | 0.26 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.32 |
| Sundry debtors | 2.60 | 4.22 | 7.80 | 9.85 | 12.79 | 11.67 | 14.62 |
| Cash & bank balances | 0.74 | 2.81 | 9.31 | 7.42 | 15.41 | 6.98 | 1.47 |
| Loans & advances | 15.77 | 14.02 | 7.56 | 2.81 | 9.98 | 3.85 | 6.27 |
| Total current assets | 19.11 | 21.05 | 24.67 | 20.08 | 38.22 | 22.54 | 22.68 |
| Total current liabilities | 3.16 | 2.66 | 11.77 | 4.01 | 7.46 | 8.64 | 11.55 |
| Net working capital | 15.95 | 18.39 | 12.90 | 16.07 | 30.76 | 13.90 | 11.13 |
| Total assets | 21.17 | 23.10 | 21.86 | 24.16 | 34.49 | 30.08 | 23.84 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.81 | 9.31 | 7.42 | 15.41 | 6.98 | 1.47 | 0.30 |
| Net cash from operating activities | (2.45) | (9.82) | 4.85 | (1.56) | 8.26 | 1.83 | (15.18) |
| Net cash from investing activities | (0.24) | 3.07 | (1.79) | (4.28) | (1.13) | (0.31) | (0.01) |
| Net cash from financing activities | 0.00 | 0.24 | (1.17) | (2.15) | 1.30 | 3.99 | 16.36 |
| Net change in cash | (2.69) | (6.51) | 1.90 | (7.99) | 8.43 | 5.51 | 1.17 |
| Closing cash | 0.74 | 2.81 | 9.31 | 7.42 | 15.41 | 6.98 | 1.47 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -37.9% | -37.0% | -21.3% | -30.2% | +17.6% | +131.6% | - |
| EBITDA growth | +53.1% | -669.2% | +91.2% | -276.4% | +72.5% | +37.9% | - |
| PBT growth | +42.3% | -428.1% | +70.9% | - | +474.0% | +46.3% | +241.9% |
| Net income growth | -1288.5% | +117.2% | -140.1% | -66.8% | +706.4% | +28.2% | - |
| Revenue CAGR (3Y) | -32.4% | -29.8% | -13.6% | +23.9% | +100.9% | +279.1% | - |
| EBITDA CAGR (3Y) | -31.7% | - | - | - | +139.2% | +252.0% | - |
| Profitability & leverage | |||||||
| Net income margin | -22.0% | -22.5% | -4.7% | -5.9% | +17.4% | +2.5% | +4.6% |
| Return on capital employed | - | -4.7% | -3.1% | +9.5% | +38.0% | +10.8% | +12.3% |
| Return on net worth | - | +1.2% | -6.8% | +15.9% | +55.8% | +8.4% | +8.8% |
| Debt / equity | - | 0.01 | 0.02 | 0.24 | 0.71 | 1.05 | 0.76 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.14 | 0.38 | 0.35 | 0.10 |
| Interest cover | 0.00 | 0.00 | -17.27 | -4.34 | 9.32 | 43.82 | 39.09 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 7.50 | 10.87 | 14.29 | 17.58 | 11.70 | 9.60 |
| Inventory turnover | - | 0.00 | 0.00 | 2,278.50 | 1,633.00 | 308.67 | 74.97 |
| Debtors turnover | - | 3.76 | 4.07 | 4.03 | 5.34 | 4.23 | 2.65 |
| EPS (₹) | (3.05) | (5.03) | (1.66) | (2.66) | 11.27 | 1.39 | 1.09 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 22.63 | 21.64 | 22.98 | 23.93 | 13.55 | 12.44 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.07 | 0.13 | 0.09 | 0.85 | 0.23 | 0.16 | 0.08 |
| Revenue growth (YoY) | -88.2% | -69.6% | -18.8% | +12.5% | +123.7% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Total expenses | 0.17 | 0.24 | 0.14 | 0.20 | 0.78 | 0.39 | 0.25 | 0.15 |
| EBITDA | (0.07) | (0.17) | (0.01) | (0.11) | 0.07 | (0.16) | (0.09) | (0.07) |
| EBITDA margin | -70.0% | -242.9% | -7.7% | -122.2% | +8.2% | -69.6% | -56.3% | -87.5% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.07) | (0.17) | (0.01) | (0.11) | 0.07 | (0.16) | (0.09) | (0.05) |
| Tax | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.14 | 0.85 | 3.53 | 0.81 | 0.99 | 0.98 | 1.42 |
| Revenue growth | +34.1% | -75.9% | +335.8% | -18.2% | +1.0% | -31.0% | - |
| Other income | 0.00 | 0.02 | 0.02 | 0.03 | 0.05 | 0.14 | 0.01 |
| Total expenses | 1.36 | 1.30 | 3.51 | 3.41 | 0.63 | 0.95 | 1.26 |
| Employee cost | 0.00 | 0.16 | 0.17 | 0.17 | 0.20 | 0.15 | 0.13 |
| EBITDA | (0.22) | (0.45) | 0.02 | (2.60) | 0.36 | 0.03 | 0.16 |
| EBITDA margin | -19.3% | -52.9% | +0.6% | -321.0% | +36.4% | +3.1% | +11.3% |
| Depreciation | 0.02 | 0.02 | 0.01 | 0.06 | 0.05 | 0.04 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Profit before tax | (0.24) | (0.45) | 0.03 | (2.63) | 0.36 | 0.11 | 0.17 |
| Tax | 0.01 | 0.00 | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 |
| Net profit | (0.25) | (0.45) | 0.03 | (0.30) | 0.36 | 0.11 | 0.17 |
| Net profit margin | -21.9% | -52.9% | +0.9% | -37.0% | +36.4% | +11.2% | +12.0% |
| EPS (₹) | (0.24) | (0.44) | 0.02 | (2.59) | 0.36 | 0.10 | 0.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves & surplus | (1.86) | (1.61) | (1.17) | (1.20) | 1.42 | 1.06 | 0.97 |
| Shareholders' funds (net worth) | 8.24 | 8.49 | 8.93 | 8.90 | 11.52 | 11.16 | 11.07 |
| Secured loans | 0.50 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.23 |
| Total debt | 0.50 | 0.24 | 0.00 | 0.00 | 0.00 | 0.14 | 0.23 |
| Total liabilities | 8.74 | 8.73 | 8.93 | 8.90 | 11.52 | 11.30 | 11.30 |
| Assets | |||||||
| Gross block | 0.29 | 0.29 | 0.24 | 0.24 | 0.43 | 0.30 | 0.11 |
| Net block | 0.12 | 0.13 | 0.10 | 0.12 | 0.34 | 0.26 | 0.11 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 8.66 | 8.66 | 8.66 | 8.66 | 8.66 | 8.41 | 8.41 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.32 |
| Sundry debtors | 0.03 | 0.23 | 3.95 | 0.13 | 0.22 | 0.41 | 0.17 |
| Cash & bank balances | 0.03 | 0.05 | 0.03 | 0.06 | 0.05 | 0.02 | 0.03 |
| Loans & advances | 0.10 | 0.04 | 0.00 | 0.00 | 2.29 | 2.25 | 2.60 |
| Total current assets | 0.16 | 0.32 | 3.98 | 0.19 | 2.60 | 2.72 | 3.12 |
| Total current liabilities | 0.25 | 0.45 | 3.83 | 0.09 | 0.08 | 0.10 | 0.35 |
| Net working capital | (0.09) | (0.13) | 0.15 | 0.10 | 2.52 | 2.62 | 2.77 |
| Total assets | 8.74 | 8.73 | 8.93 | 8.90 | 11.52 | 11.30 | 11.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.05 | 0.03 | 0.06 | 0.05 | 0.02 | 0.03 | 0.02 |
| Net cash from operating activities | (0.29) | (0.17) | (0.03) | (0.08) | 0.55 | 0.27 | (0.01) |
| Net cash from investing activities | 0.00 | (0.05) | 0.00 | 0.09 | (0.38) | (0.19) | (0.07) |
| Net cash from financing activities | 0.26 | 0.24 | 0.00 | 0.00 | (0.14) | (0.09) | 0.09 |
| Net change in cash | (0.03) | 0.03 | (0.03) | 0.01 | 0.03 | (0.01) | 0.01 |
| Closing cash | 0.03 | 0.05 | 0.03 | 0.06 | 0.05 | 0.02 | 0.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +34.1% | -75.9% | +335.8% | -18.2% | +1.0% | -31.0% | - |
| EBITDA growth | +51.1% | -2350.0% | +100.8% | -822.2% | +1100.0% | -81.3% | - |
| PBT growth | +46.7% | - | +9998.0% | - | +227.3% | -35.3% | -54.1% |
| Net income growth | +44.4% | -1600.0% | +110.0% | -183.3% | +227.3% | -35.3% | - |
| Revenue CAGR (3Y) | +12.1% | -5.0% | +53.3% | -17.1% | -47.3% | -1.3% | +55.2% |
| EBITDA CAGR (3Y) | -56.1% | - | -12.6% | - | 0.0% | -27.9% | - |
| Profitability & leverage | |||||||
| Net income margin | -21.9% | -52.9% | +0.9% | -322.2% | +36.4% | +11.2% | +12.0% |
| Return on capital employed | - | 0.0% | +0.2% | 0.0% | +2.2% | +0.7% | +1.4% |
| Return on net worth | - | 0.0% | +0.2% | 0.0% | +2.2% | +0.6% | +1.4% |
| Debt / equity | - | 0.01 | 0.00 | 0.00 | 0.01 | 0.02 | 0.03 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -200.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 3.21 | 14.71 | 2.42 | 2.71 | 4.78 | 23.67 |
| Inventory turnover | - | 0.00 | 0.00 | 40.50 | 24.75 | 5.44 | 4.44 |
| Debtors turnover | - | 0.41 | 1.73 | 4.63 | 3.14 | 3.38 | 0.88 |
| EPS (₹) | (0.24) | (0.44) | 0.02 | (2.59) | 0.36 | 0.10 | 0.17 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 8.40 | 8.84 | 8.82 | 11.41 | 11.05 | 10.96 |
Upgrade to premium
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Combat Drugs
Premium access
Complete news archive for Combat Drugs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Combat Drugs
Combat Drugs was founded in 1986.
Combat Drugs is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Combat Drugs has 21 employees.
The primary company behind Combat Drugs, Icp Solutions Limited, reported revenue of ₹9.89 Cr for FY 2025, up 52% year on year.
Combat Drugs was established in 1986 in Hyderabad, India, within the pharmaceutical sector. Branded formulations are produced alongside custom manufacturing services. Operations encompass solid dosage forms, including single- and multi-ingredient tablets and capsules in various coatings and designs, as well as liquid orals and ointments. Focus is placed on meeting formulation needs through these categories.
Yes, Combat Drugs is publicly traded on BSE under the ticker symbol DECIPHER.
Combat Drugs is associated with 2 legal entities: Icp Solutions Limited, Decipher Labs Limited.
The legal entities of Combat Drugs currently have 11 directors, including Sridhara Tulasi Priyanka, Komal Srivastava, Abhichakra Gudipudi and others.